Mavoglurant

Mavoglurant
	Metil (3aR,4S,7aR)-4-hidroksi-4-[(3-metilfenil)etinil]oktahidro-1H-indol-1-karboksilat
Drugi nazivi	AFQ056
Identifikacija
CAS registarski broj	543906-09-8
PubChem	9926832
ChemSpider	8102466
UNII	GT0I9SV4F6
Jmol-3D slike	Slika 1
SMILES
	O=C(OC)N3[C@@H]2CCC[C@@](O)(C#Cc1cccc(c1)C)[C@@H]2CC3
InChI
	InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1 ; Kod: ZFPZEYHRWGMJCV-ZHALLVOQSA-N InChI=1/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1; Kod: ZFPZEYHRWGMJCV-ZHALLVOQBN
Svojstva
Molekulska formula	C19H23NO3
Molarna masa	313.39 g mol−1
	; ; Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala
	Infobox references

Mavoglurant (AFQ-056) je eksperimentalni kandidat leka za tretman fragilnog X sindroma.^[4] On deluje kao antagonist metabotropnog glutamatnog receptora 5 (mGlu₅).^[5]

Mavoglurant razvija Novartis i trenutno je u fazi III kliničkih ispitivanja.^[4]^[6] U slučaju uspešnog ishoda ispitivanja, on će biti privi lek koji tretira poremećaju umesto simptoma fragilnog X sindroma.^[7]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ ^4,0 ^4,1 P. Cole (2012). „Mavoglurant”. Drugs of the Future 37 (1): 7–12. DOI:10.1358/dof.2012.37.1.1772147.
↑ Levenga, J; Hayashi, S; De Vrij, FM; Koekkoek, SK; Van Der Linde, HC; Nieuwenhuizen, I; Song, C; Buijsen, RA et al. (2011). „AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome”. Neurobiology of disease 42 (3): 311–7. DOI:10.1016/j.nbd.2011.01.022. PMID 21316452.
↑ Jacquemont, S.; Curie, A.; Des Portes, V.; Torrioli, M. G.; Berry-Kravis, E.; Hagerman, R. J.; Ramos, F. J.; Cornish, K. et al. (2011). „Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome is Associated with Differential Response to the mGluR5 Antagonist AFQ056”. Science Translational Medicine 3 (64): 64ra1. DOI:10.1126/scitranslmed.3001708. PMID 21209411.
↑ „AFQ056 drug improves symptoms in Fragile X patients: Study”. news-medical.net. 9. 1. 2011..

Spoljašnje veze

Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[Cole-4] 4,0 ^4,1 P. Cole (2012). „Mavoglurant”. Drugs of the Future 37 (1): 7–12. DOI:10.1358/dof.2012.37.1.1772147.

[5] Levenga, J; Hayashi, S; De Vrij, FM; Koekkoek, SK; Van Der Linde, HC; Nieuwenhuizen, I; Song, C; Buijsen, RA et al. (2011). „AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome”. Neurobiology of disease 42 (3): 311–7. DOI:10.1016/j.nbd.2011.01.022. PMID 21316452.

[6] Jacquemont, S.; Curie, A.; Des Portes, V.; Torrioli, M. G.; Berry-Kravis, E.; Hagerman, R. J.; Ramos, F. J.; Cornish, K. et al. (2011). „Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome is Associated with Differential Response to the mGluR5 Antagonist AFQ056”. Science Translational Medicine 3 (64): 64ra1. DOI:10.1126/scitranslmed.3001708. PMID 21209411.

[7] „AFQ056 drug improves symptoms in Fragile X patients: Study”. news-medical.net. 9. 1. 2011..

[1]

[2]

[3]

[4]

[5]

[6]

[7]